PubMed, doi:10.1016/j.ejogrb.2014.02.036.Ahern, Thomas P., et al
It is not a GLP-1, not a weight-loss drug, and should not be treated as one
Mechanisms of action: two distinct cascades BPC-157: NO pathway modulation and growth factor expression Preclinical studies have suggested that BPC-157 acts primarily through three axes: NO (nitric oxide) pathway : BPC-157 modulates endothelial NO signaling, favoring local vasodilation and perfusion of injured tissues VEGF-R2 expression and angiogenesis : animal models have shown increased formation of new capillaries at the injury site Interactions with dopaminergic, serotonergic and GABAergic pathways : BPC-157 exhibits a pleiotropic profile influencing neurological and digestive healing Documented strengths (animal models): healing of tendons, ligaments, gastrointestinal mucosa, bone, teeth, vessels, cornea
Recently, an in vitro study showed that in the presence of NT and NTS2, D2R exhibits a reduced affinity for dopamine similar to NTS1 (Koschatzky and Gmeiner, 2012)
PMID: 16049521, DOI: 10.1038/sj.jhh.1001895
In 2021, 13% of respondents offered three or more plan types in total the largest plan type accounts for 82% of workers covered by health benefits and the largest two plan types represents 98%
